Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Signs Columbia University CLIA Lab to Validate microRNA-Based CUP Dx

NEW YORK (GenomeWeb News) — Rosetta Genomics today said that a Columbia University Medical Center lab will validate the company’s microRNA-based diagnostics program for Cancer of Unknown Primary.
The agreement calls for the company to provide the school’s Clinical Laboratory Improvement Amendments-certified lab with its protocol for diagnosing the primary origin of metastatic cancers, which will then be tested and validated using blinded samples provided by the medical center.
The alliance is Rosetta Genomics' first agreement that aims to clinically validate one of its cancer diagnostics. The company is developing several diagnostics at its R&D facilities in Israel and the United States.
The CUP diagnostic, currently in the final stages of development, is designed to help clinicians identify the origin of tumors that have metastasized throughout the body.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.